首页|含米诺环素、克拉霉素的铋剂四联方案在青霉素过敏的幽门螺杆菌感染初治患者中的应用价值

含米诺环素、克拉霉素的铋剂四联方案在青霉素过敏的幽门螺杆菌感染初治患者中的应用价值

扫码查看
目的 评价含米诺环素、克拉霉素的铋剂四联方案在青霉素过敏的幽门螺杆菌(Helicobacter pylori,H.pylori)感染初治患者中应用的根除疗效、依从性及安全性等情况.方法 回顾性分析 2022 年 9 月至 2023 年 7 月于清华大学第一附属医院就诊的H.pylori感染初治且青霉素过敏的 219 例患者的临床资料,其中 RMiCB组(69 例)为雷贝拉唑+米诺环素+克拉霉素+复方铝酸铋颗粒方案;RMeCB组(71 例)为雷贝拉唑+甲硝唑+克拉霉素+复方铝酸铋颗粒方案;RLCB组(79 例)为雷贝拉唑+左氧氟沙星+克拉霉素+复方铝酸铋颗粒方案,疗程均为 14 d,电话随访患者用药安全性、依从性及 H.pylori根除情况.结果 三组患者的基线资料差异无统计学意义(P>0.05).RMiCB组、RMeCB组、RLCB组患者 H.pylori根除率根据意向性分析(intention-to-treat analysis,ITT)分别为 86.9%(60/69)、60.5%(43/71)、62.0%(49/79),符合方案分析(per-protocol analysis,PP)分别为 90.9%(60/66)、66.2%(43/65)、68.1%(49/72).按照 PP 分析,RMiCB组患者 H.pylori根除率高于 RMeCB、RLCB组,差异有统计学意义(χ2=13.428,P=0.001),RMeCB、RLCB组 H.pylori根除率差异无统计学意义(χ2=0.056,P=0.857).RMiCB 组、RMeCB 组、RLCB 组患者药物不良反应发生率分别为 13.0%(9/69)、16.9%(12/71)、16.5%(13/79),差异无统计学意义(χ2=0.479,P=0.797).结论 含米诺环素、克拉霉素的铋剂四联方案在青霉素过敏的 H.pylori感染初治患者中根除效果较好,且具有较高的依从性,可考虑作为一线治疗的备选方案.
The application value of the quadruple therapy regimen containing bismuth,Mino-cycline and Clarithromycin in the initial treatment patients with Helicobacter pylori infection allergic to penicillin
Objective To evaluate the eradication efficacy,compliance and safety of the bismuth quadruple regimen containing Minocycline and Clarithromycin in the initial treatment of H.pylori infection among patients with penicillin al-lergy.Methods This study used a retrospective analysis to collect clinical data of 219 patients with H.pylori infection allergic to penicillin treated at the First Hospital of Tsinghua University from Sep.2022 to Jul.2023.Group RMiCB(69 cases)received a regimen of Rabeprazole,Minocycline,Clarithromycin and compound bismuth aluminate granules.Group RMeCB(71 cases)received the regimen of Rabeprazole,Metronidazole,Clarithromycin and compound bismuth aluminate granules.Group RLCB(79 cases)was treated with a regimen of Rabeprazole,Levofloxacin,Clarithromycin and compound bismuth aluminate granules.The treatment courses were all 14 days,and telephone follow-up was con-ducted to assess patient safety,compliance and H.pylori eradication.Results There was no significant difference in baseline data among the three groups(P>0.05).According to the intention-to-treat analysis(ITT),the H.pylori eradi-cation rates were 86.9%(60/69)in group RMiCB,60.5%(43/71)in group RMeCB,and 62.0%(49/79)in group RLCB;the per-protocol analysis(PP)showed that the rates were 90.9%(60/66)in group RMiCB,66.2%(43/65)in group RMeCB,and 68.1%(49/72)in group RLCB.According to the PP analysis,the H.pylori eradication rate in group RMiCB was higher than that in group RMeCB and group RLCB,with a statistically significant difference(χ2=13.428,P=0.001),while there was no statistical difference in the H.pylori eradication rates between group RMeCB and group RLCB(χ2=0.056,P=0.857).The incidence of drug adverse reactions was 13.0%(9/69)in group RMiCB,16.9%(12/71)in group RMeCB,and 16.5%(13/79)in group RLCB,with no significant difference(χ2=0.479,P=0.797).Conclusion The quadruple therapy regimen containing Bismuth,Minocycline,and Clarithromy-cin is effective in eradicating H.pylori infection among patients with penicillin allergy in initial treatment,has high com-pliance,and can be considered as an alternative treatment option.

Helicobacter pyloriMinocyclineBismuth quadruple regimenPenicillin allergyEradication therapy

韩强、程艳丽、刘秀清、王亚丽、董佳璐、庞梦瑶、张宏娜、梁辰飞、张亮

展开 >

清华大学第一附属医院消化内科,北京 100016

幽门螺杆菌 米诺环素 铋剂四联方案 青霉素过敏 根除治疗

2024

胃肠病学和肝病学杂志
郑州大学

胃肠病学和肝病学杂志

CSTPCD
影响因子:1.029
ISSN:1006-5709
年,卷(期):2024.33(5)
  • 21